Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - afinitor
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpda6b4339076346d51f1c98fff12b57db
identifier: http://ema.europa.eu/identifier
/EU/1/09/538/009
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Afinitor 2.5 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-da6b4339076346d51f1c98fff12b57db
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/09/538/009
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - afinitor
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Afinitor is an anticancer medicine containing the active substance everolimus. Everolimus reduces the blood supply to the tumour and slows down the growth and spread of cancer cells.
Afinitor is used to treat adult patients with:
hormone receptor-positive advanced breast cancer in postmenopausal women, in whom other treatments (so called non-steroidal aromatase inhibitors ) no longer keep the disease under control. It is given together with a medicine called exemestane, a steroidal aromatase inhibitor, which is used for hormonal anticancer therapy.
advanced tumours called neuroendocrine tumours that originate from the stomach, bowels, lung or pancreas. It is given if the tumours are inoperable and do not overproduce specific hormones or other related natural substances.
advanced kidney cancer (advanced renal cell carcinoma), where other treatments (so-called VEGF-targeted therapy ) have not helped stop your disease.
Afinitor will only be prescribed for you by a doctor with experience in cancer treatment. Follow all the doctor s instructions carefully. They may differ from the general information contained in this leaflet. If you have any questions about Afinitor or why it has been prescribed for you, ask your doctor.
Do not take Afinitor
if you are allergic to everolimus, to related substances such as sirolimus or temsirolimus, or to any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.
Warnings and precautions Talk to your doctor before taking Afinitor:
Afinitor may also:
Tell your doctor if you experience these symptoms.
You will have regular blood tests during treatment. These will check the amount of blood cells (white blood cells, red blood cells and platelets) in your body to see if Afinitor is having an unwanted effect on these cells. Blood tests will also be carried out to check your kidney function (level of creatinine) and liver function (level of transaminases) and your blood sugar and cholesterol levels. This is because these can also be affected by Afinitor.
Children and adolescents Afinitor is not to be used in children or adolescents (age below 18 years).
Other medicines and Afinitor Afinitor may affect the way some other medicines work. If you are taking other medicines at the same time as Afinitor, your doctor may need to change the dose of Afinitor or the other medicines.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
The following may increase the risk of side effects with Afinitor:
The following may reduce the effectiveness of Afinitor:
These medicines should be avoided during your treatment with Afinitor. If you are taking any of them, your doctor may switch you to a different medicine, or may change your dose of Afinitor.
Afinitor with food and drink Avoid grapefruit and grapefruit juice while you are on Afinitor. It may increase the amount of Afinitor in the blood, possibly to a harmful level.
Pregnancy, breast-feeding and fertility
Pregnancy Afinitor could harm your unborn baby and is not recommended during pregnancy. Tell your doctor if you are pregnant or think that you may be pregnant. Your doctor will discuss with you whether you should take this medicine during your pregnancy.
Women who could potentially become pregnant should use highly effective contraception during treatment and for up to 8 weeks after ending treatment. If, despite these measures, you think you may have become pregnant, ask your doctor for advice before taking any more Afinitor.
Breast-feeding Afinitor could harm your breast-fed baby. You should not breast-feed during treatment and for 2 weeks after the last dose of Afinitor. Tell your doctor if you are breast-feeding.
Female fertility Absence of menstrual periods (amenorrhoea) has been observed in some female patients receiving Afinitor.
Afinitor may have an impact on female fertility. Talk to your doctor if you wish to have children.
Male fertility Afinitor may affect male fertility. Talk to your doctor if you wish to father a child. Driving and using machines If you feel unusually tired (fatigue is a very common side effect), take special care when driving or using machines.
Afinitor contains lactose Afinitor contains lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is 10 mg, taken once a day. Your doctor will tell you how many tablets of Afinitor to take.
If you have liver problems, your doctor may start you on a lower dose of Afinitor (2.5, 5 or 7.5 mg per day).
If you experience certain side effects while you are taking Afinitor (see section 4), your doctor may lower your dose or stop treatment, either for a short time or permanently.
Take Afinitor once a day, at about the same time every day, consistently either with or without food.
Swallow the tablet(s) whole with a glass of water. Do not chew or crush the tablets.
If you take more Afinitor than you should
If you forget to take Afinitor If you miss a dose, take your next dose as scheduled. Do not take a double dose to make up for the forgotten tablets.
If you stop taking Afinitor Do not stop taking Afinitor unless your doctor tells you to.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking Afinitor and seek medical help immediately if you experience any of the following signs of an allergic reaction:
Serious side effects of Afinitor include:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
If you experience any of these side effects, tell your doctor immediately as this might have life-threatening consequences.
Other possible side effects of Afinitor include:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Not known (frequency cannot be estimated from the available data)
If these side effects get severe please tell your doctor and/or pharmacist. Most of the side effects are mild to moderate and will generally disappear if your treatment is interrupted for a few days.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister foil. The expiry date refers to the last day of that month.
Do not store above 25 C.
Store in the original package in order to protect from light and moisture.
Open the blister just before taking the tablets.
Do not use this medicine if any pack is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Afinitor contains
What Afinitor looks like and contents of the pack Afinitor 2.5 mg tablets are white to slightly yellowish, elongated tablets. They are engraved with LCL on one side and NVR on the other. Afinitor 5 mg tablets are white to slightly yellowish, elongated tablets. They are engraved with 5 on one side and NVR on the other. Afinitor 10 mg tablets are white to slightly yellowish, elongated tablets. They are engraved with UHE on one side and NVR on the other.
Afinitor 2.5 mg is available in blister packs containing 30 or 90 tablets. Afinitor 5 mg and Afinitor 10 mg are available in blister packs containing 10, 30 or 90 tablets. Not all pack sizes or strengths may be marketed in your country.
Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland
Manufacturer Novartis Farmac utica SA Gran Via de les Corts Catalanes, 08013 Barcelona Spain
Novartis Pharma GmbH Roonstrasse D-90429 Nuremberg Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16
Novartis Bulgaria EOOD .: +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0
Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20
Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133
Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-da6b4339076346d51f1c98fff12b57db
Resource Composition:
Generated Narrative: Composition composition-en-da6b4339076346d51f1c98fff12b57db
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/09/538/009status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - afinitor
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpda6b4339076346d51f1c98fff12b57db
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpda6b4339076346d51f1c98fff12b57db
identifier:
http://ema.europa.eu/identifier
/EU/1/09/538/009type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Afinitor 2.5 mg tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en